HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Hematology613 papers

Acute myeloid leukemia

Last edited: 4/23/2026

Overview

Acute myeloid leukemia (AML) is a hematologic malignancy characterized by the uncontrolled proliferation of myeloid progenitor cells. It significantly impacts survival and quality of life, necessitating tailored treatment approaches based on patient-specific factors. 20

Diagnosis

Morphology and Immunophenotyping: Essential for identifying blast cell populations and immunophenotypic markers. 20

Cytogenetics and Molecular Markers: Karyotyping, FISH, and mutation analysis (e.g., FLT3, NPM1, TP53) for risk stratification. 21

Measurable Residual Disease (MRD): Monitoring MRD levels post-induction therapy to guide further treatment decisions. 1 23

Bone Marrow Biopsy: Evaluation of cellularity and blast percentage crucial for diagnosis and monitoring response. 27

Management

Induction Therapy: Anthracycline (e.g., daunorubicin 60-90 mg/m2) + cytarabine 6 13

Consolidation Therapy: Based on risk stratification (e.g., high-dose cytarabine, allogeneic hematopoietic cell transplantation for high-risk patients). 20

Maintenance Therapy: Oral azacitidine for selected patients to improve outcomes and reduce hospitalizations. 57

Targeted Therapies: Venetoclax-based combinations, FLT3 inhibitors, and IDH inhibitors for specific genetic mutations. 8 14 64

Supportive Care: Management of cardiotoxicity, infection prophylaxis, and hematologic support (e.g., antifungal prophylaxis). 3 13 37

Special Populations

Elderly Patients: Less intensive regimens recommended; consider fitness and comorbidities. 2 19

Comorbidities: Cardiovascular disease necessitates careful anthracycline dosing and monitoring (e.g., heart failure risk scores). 3 11 33

Pediatrics: Increased risk of cardiotoxicity and unique complications like splenic infarction. 50 72

Key Recommendations

Induction Therapy with Anthracycline and Cytarabine: Standard regimen for newly diagnosed AML patients. (Evidence: Strong 6 13)

Risk Stratification Based on Cytogenetics and MRD: Guide consolidation and maintenance therapy decisions. (Evidence: Strong 1 21 23)

Consider Maintenance Therapy with Azacitidine for Selected Patients: To improve long-term outcomes and quality of life. (Evidence: Moderate 57)

Tailored Approaches for Older Adults: Use less intensive regimens considering patient fitness and comorbidities. (Evidence: Moderate 2 19)

Close Monitoring for Cardiotoxicity: Especially in patients receiving anthracycline-based therapy. (Evidence: Moderate 3 11 33)

References

Showing 100 most recent of 229 indexed papers.

1 Cloos J, Valk PJM, Thiede C, Döhner K, Roboz GJ, Wood BL et al.. 2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party. Blood 2026. link 2 Sekeres MA, Mattison R, Artz A, Baer MR, Chua CC, Demichelis-Gómez R et al.. American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood advances 2026. link 3 Geels J, van Rhenen A, Gradowska P, Asselbergs FW, Linschoten M. Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis. Leukemia 2026. link 4 Vydra J, Ferhat AT, Kröger N, Gedde-Dahl T, Eder M, Schroeder T et al.. Posttransplant cyclophosphamide versus antithymocyte globulin in patients with cardiovascular comorbidity undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukaemia in first complete remission from unrelated donors: a retrospective matched-pair analysis from the ALWP of the EBMT. Bone marrow transplantation 2026. link 5 Tominaga R, Fujiwara SI, Honda S, Yokoyama D, Noguchi A, Furuki S et al.. Significance of the tendency for relative bradycardia during induction therapy for acute myeloid leukemia. International journal of hematology 2026. link 6 Dendorfer SM, Schmidt-Brücken K, Kramer M, Steffen B, Schliemann C, Mikesch JH et al.. Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy. American journal of hematology 2026. link 7 Lin Y, Liu P, Zhuang Q, Deng H, Liu X, Wang Y et al.. Prognostic impact of extramedullary disease in acute myeloid leukemia: A meta-analysis. International journal of cancer 2025. link 8 Gil-Sierra MD, Mantopoulos T, Barouma I, Hauch O, Teng Z, Fernandez C et al.. Indirect treatment comparison of ivosidenib and other therapies in patients with newly diagnosed acute myeloid leukemia. Future oncology (London, England) 2025. link 9 Skok K, Zacharias M, Verheyen N, Hatzl S, Scholz L, Langner C et al.. Myeloid sarcoma of the heart-A clinicopathological correlation. Wiener klinische Wochenschrift 2025. link 10 Gündoğdu F, Agaimy A, Aytaç S, Hazar V, Üner A, Kösemehmetoğlu K. Myeloid sarcoma with RBM15::MRTFA (MKL1) mimicking vascular neoplasm. Virchows Archiv : an international journal of pathology 2025. link 11 Wu M, Russell K, Shaw CM, Halpern AB, Ghiuzeli C, Appelbaum JS et al.. Predictors of Cardiac Recovery in Adults With AML Who Develop Heart Failure During Treatment. JCO oncology practice 2025. link 12 Jensen RH, Teglgaard C, Jensen JF, Baech J, Marcher CW, Roug AS et al.. Cardiotoxicity in patients with acute myeloid leukaemia following anthracycline-containing chemotherapy: A population-based matched cohort study. British journal of haematology 2025. link 13 He H, Wen X, Zheng H. Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis. Hematology (Amsterdam, Netherlands) 2024. link 14 Mohebbi A, Shahriyary F, Farrokhi V, Bandar B, Saki N. A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia. Leukemia research 2024. link 15 Ng SWK. Characterization of relapse-supportive monocytic cells in acute myeloid leukemia. Cell reports. Medicine 2024. link 16 Hahn W, Ahmadi N, Hoffmann K, Eckardt JN, Sedlmayr M, Wolfien M. Synthetic Data Generation in Hematology - Paving the Way for OMOP and FHIR Integration. Studies in health technology and informatics 2024. link 17 Dall'Olio D, Sträng E, Turki AT, Tettero JM, Barbus M, Schulze-Rath R et al.. Covering Hierarchical Dirichlet Mixture Models on binary data to enhance genomic stratifications in onco-hematology. PLoS computational biology 2024. link 18 Paim Miranda DL, Orathes Ponte Silva AM, Pereira Ferreira D, Teixeira da Silva L, Lins-Kusterer L, Queiroz Crusoé E et al.. Variability in the perception of palliative care and end-of-life care among hematology professionals from the same reference center in Bahia, Brazil: A descriptive cross-sectional study. Sao Paulo medical journal = Revista paulista de medicina 2024. link 19 Extermann M, Artz A, Rebollo MA, Klepin HD, Krug U, Loh KP et al.. Treating acute myelogenous leukemia in patients aged 70 and above: Recommendations from the International Society of Geriatric Oncology (SIOG). Journal of geriatric oncology 2024. link 20 Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM et al.. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2023. link 21 Bidet A, Quessada J, Cuccuini W, Decamp M, Lafage-Pochitaloff M, Luquet I et al.. Cytogenetics in the management of acute myeloid leukemia and histiocytic/dendritic cell neoplasms: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH). Current research in translational medicine 2023. link 22 Daver NG, Iqbal S, Renard C, Chan RJ, Hasegawa K, Hu H et al.. Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis. Journal of hematology & oncology 2023. link 23 Zhang X, Grimes HL. Improved detection of measurable residual disease in acute myeloid leukemia. Science advances 2023. link 24 . A Trifunctional Natural Killer Cell Engager Can Target CD123+ Leukemia. Cancer discovery 2023. link 25 Mansour MA, Burns TC, El-Sokkary S, Ayad AA. A 42-Year-Old Man with a Seizure. NEJM evidence 2023. link 26 Atsou KM, Rachet B, Cornet E, Chretien ML, Rossi C, Remontet L et al.. Factors influencing access to specialised haematology units during acute myeloblastic leukaemia patient care: A population-based study in France. Cancer medicine 2023. link 27 Sarkis R, Burri O, Royer-Chardon C, Schyrr F, Blum S, Costanza M et al.. MarrowQuant 2.0: A Digital Pathology Workflow Assisting Bone Marrow Evaluation in Experimental and Clinical Hematology. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2023. link 28 Marchesi F, Salmanton-García J, Emarah Z, Piukovics K, Nucci M, López-García A et al.. COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). Haematologica 2023. link 29 Gaugler M, Swinger N, Rahrig AL, Skiles J, Rowan CM. Multiple Organ Dysfunction and Critically Ill Children With Acute Myeloid Leukemia: Single-Center Retrospective Cohort Study. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2023. link 30 Koets V, Montagnini M. Acute Myeloid Leukemia: Challenges in Delivering End-of-Life Care. The American journal of hospice & palliative care 2023. link 31 Djulejic V, Petrovic B, Jevtic J, Vujacic M, Clarke BL, Cirovic A et al.. The role of cadmium in the pathogenesis of myeloid leukemia in individuals with anemia, deficiencies in vitamin D, zinc, and low calcium dietary intake. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) 2023. link 32 Ghazaey Zidanloo S, Jahantigh D, Amini N. Vitamin D-Binding Protein and Acute Myeloid Leukemia: A Genetic Association Analysis in Combination with Vitamin D Levels. Nutrition and cancer 2023. link 33 Doukas PG, Cascino GJ, Meng Z, Baldridge AS, Kang Y, Scherrer-Crosbie M et al.. External validation of a heart failure risk score in patients with acute myeloid leukemia. Leukemia & lymphoma 2023. link 34 Nader M, Bonde P, Massaro S, Giuliano JS, Shah N. The Use of Extracorporeal Membrane Oxygenation as a Bridge to Bone Marrow Transplantation in a Patient With High-risk Acute Myeloid Leukemia. Journal of pediatric hematology/oncology 2023. link 35 Faiz AS, Guo S, Sridharan A, Lin Y, Philipp CS. Venous thromboembolism and acute myeloid leukemia: risk factors and mortality in elderly white, black and Asian patients. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2023. link 36 Li L, Han C, Yu X, Shen J, Cao Y. Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis. Journal of healthcare engineering 2022. link 37 Stemler J, de Jonge N, Skoetz N, Sinkó J, Brüggemann RJ, Busca A et al.. Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. The Lancet. Haematology 2022. link00073-4) 38 Bewersdorf JP, Prebet T, Gowda L. Azacitidine maintenance in AML post induction and posttransplant. Current opinion in hematology 2022. link 39 Lipilkin PV, Kulaeva ED, Mashkina EV. Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis. Leukemia research 2022. link 40 Vandersluis S, Reid JC, Orlando L, Bhatia M. Evidence-based support for phenotypic drug discovery in acute myeloid leukemia. Drug discovery today 2022. link 41 Solana-Altabella A, Ballesta-López O, Megías-Vericat JE, Martínez-Cuadrón D, Montesinos P. Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia. Expert opinion on emerging drugs 2022. link 42 Woodard A, Eche IJ, Leak Bryant A. Telehealth Use in Rural North Carolina Counties: Perceptions Among Patients With Acute Myeloid Leukemia. Clinical journal of oncology nursing 2022. link 43 . Ceramide Accumulation Induces the Integrated Stress Response in AML. Cancer discovery 2022. link 44 Benajiba L, Kiladjian JJ. The challenge of targets and drug discovery using large-scale screening approaches in onco-hematology. Therapie 2022. link 45 . Safety Concerns Prompt Pause of Magrolimab Trials. Cancer discovery 2022. link 46 Jaddaoui S, Bencharef H, Addakiri S, Oukkache B. Aberrant Phenotype in Acute Myeloid Leukemia: Hematology Laboratory Experiment of the University Hospital of Casablanca, Morocco. Clinical laboratory 2022. link 47 van Lieshout R, Lize N, Tick LW, van Deursen J, Driessen E, Janssen T et al.. Nutrition-related problems, nutritional support practices and barriers to adherence to nutritional guidelines during intensive treatment for acute myeloid leukemia: Patients' and hematology nurses' perspectives and experiences. Clinical nutrition ESPEN 2022. link 48 Šestáková Š, Cerovská E, Šálek C, Kundrát D, Ježíšková I, Folta A et al.. A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel. Clinical epigenetics 2022. link 49 Cripe LD, Cottingham AH, Martin CE, Hoffmann ML, Sargent K, Baker LB. Bereaved Informal Caregivers Rarely Recall a Relationship Between Transfusions and Hospice in Acute Myeloid Leukemia. The American journal of hospice & palliative care 2022. link 50 Sabet K, Panigrahi A, Chung J, Dayan Y. Pediatric AML patients with acute-onset cardiomyopathy in the setting of Streptococcus viridans bacteremia after anthracyclines. Pediatric blood & cancer 2022. link 51 Koschade SE, Stratmann JA, Miesbach W, Steffen B, Serve H, Finkelmeier F et al.. Intracranial hemorrhage in newly diagnosed non-promyelocytic acute myeloid leukemia patients admitted for intensive induction chemotherapy. European journal of haematology 2022. link 52 Borgstedt-Bendixen SE, Abrahamsson J, Ha SY, Koskenvuo M, Lausen B, Palle J et al.. Abdominal Complications During Treatment for Pediatric Acute Myeloid Leukemia. Journal of pediatric hematology/oncology 2022. link 53 Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR et al.. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. Journal of the National Comprehensive Cancer Network : JNCCN 2021. link 54 Lee D, Omofoye OA, Nuño MA, Riestenberg RA, Shahlaie K. Treatment Outcomes of Intracranial Myeloid Sarcomas: A Meta-Analysis. World neurosurgery 2021. link 55 Chang Y, Guyatt GH, Teich T, Dawdy JL, Shahid S, Altman JK et al.. Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review. PloS one 2021. link 56 Modarres P, Mohamadi Farsani F, Nekouie AA, Vallian S. Meta-analysis of gene signatures and key pathways indicates suppression of JNK pathway as a regulator of chemo-resistance in AML. Scientific reports 2021. link 57 . Benefits of AML Maintenance Therapy Extend to Quality of Life and Hospitalization. The oncologist 2021. link 58 . Mutations Synergize to Alter Epigenetic and Genomic Landscape of AML. Cancer discovery 2021. link 59 . Single-Cell Sequencing Reveals Clonal Architecture of Myeloid Cancers. Cancer discovery 2021. link 60 . African American Race Predicts Poor Survival in Younger Adults with AML. The oncologist 2021. link 61 . Maintenance Therapy Improves AML Outcomes Regardless of MRD Status or Consolidation Cycles. The oncologist 2021. link 62 Ha C. The Age-Old Conundrum With Thiopurines: Are the Accumulating Risks Greater Than Benefits?. The American journal of gastroenterology 2021. link 63 Sahu KK, E Vogt B, Shanahan L, Cerny J. A Splenic Infarction Related to Parainfluenza Infection in a Patient with AML: Lessons for COVID-19. Acta bio-medica : Atenei Parmensis 2021. link 64 . Study Offers Insights on Prognostic Significance of IDH Mutations Across Age Groups in AML. The oncologist 2021. link 65 Corboy G, Othman J, Lee L, Wei A, Ivey A, Blombery P et al.. Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative. Pathology 2021. link 66 Yu S, Fan Z, Ma L, Wang Y, Huang F, Zhang Q et al.. Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes. JAMA network open 2021. link 67 Chan KY, Gill H, Li CW, Chan TSY, Au HY, Wong CY et al.. Impact of enhanced haematology palliative care services in patients with myelodysplastic syndrome and acute myeloid leukaemia: study protocol for a randomized controlled trial. Annals of palliative medicine 2021. link 68 Kattih B, Shirvani A, Klement P, Garrido AM, Gabdoulline R, Liebich A et al.. IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis. Leukemia 2021. link 69 Hosono N, Ookura M, Araie H, Morita M, Itoh K, Matsuda Y et al.. Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience. International journal of hematology 2021. link 70 Peña Domingo M, Vives Polo S, Garrido Díaz A, Coll Jordà R, Ribera Santasusana JM, Ferrá Coll C. Low doses of gemtuzumab ozogamicin in adults diagnosed with acute myeloid leukaemia. Medicina clinica 2021. link 71 Tony S, Mevada R, Joshi N. Anthracycline-related acute cardiotoxicity in a very young Omani patient with acute myeloid leukaemia. Cardiology in the young 2021. link 72 Green K, Tandon S, Ahmed M, Toscano W, O'Connor D, Ancliff P et al.. Congenital acute myeloid leukemia: challenges and lessons. A 15-year experience from the UK. Leukemia & lymphoma 2021. link 73 . Preleukemic Cells Can Be Eliminated in . Cancer discovery 2020. link 74 Marron JM. Informed consent for genetic testing in hematology. Hematology. American Society of Hematology. Education Program 2020. link 75 Sekeres MA, Guyatt G, Abel G, Alibhai S, Altman JK, Buckstein R et al.. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood advances 2020. link 76 Watson EE, Metcalfe JE, Kreher MR, Maxymiw WG, Glogauer M, Schimmer AD. Screening for Dental Infections Achieves 6-Fold Reduction in Dental Emergencies During Induction Chemotherapy for Acute Myeloid Leukemia. JCO oncology practice 2020. link 77 Dhakal P, Lyden E, Muir KE, Al-Kadhimi ZS, Koll T, Maness LJ et al.. Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia. Leukemia & lymphoma 2020. link 78 Mort MK, Sen JM, Morris AL, DeGregory KA, McLoughlin EM, Mort JF et al.. Evaluation of cardiomyopathy in acute myeloid leukemia patients treated with anthracyclines. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2020. link 79 Ho VT, Martin AS, Pérez WS, Steinert P, Zhang MJ, Chirnomas D et al.. Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2020. link 80 Hernandez Burgos P, Patel J, Chen A. Ivosidenib induction therapy complicated by myopericarditis and cardiogenic shock: A case report and literature review. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2020. link 81 Marcault C, Venton G, Gastaud L, Mannone L, Rey J, D'Incan E et al.. Alternative Effective and Safe Induction Regimens for Newly Diagnosed Acute Myeloid Leukemia in Patients With Cardiac Contraindication to Anthracyclines. Clinical lymphoma, myeloma & leukemia 2020. link 82 Bamezai S, Buske C. Cutting Off Leukemogenesis: Hydra-like Plasticity of Mature Leukemic Cells. Cell stem cell 2019. link 83 Keiffer G, Palmisiano N. Acute Myeloid Leukemia: Update on Upfront Therapy in Elderly Patients. Current oncology reports 2019. link 84 Qasrawi A, Bahaj W, Qasrawi L, Abughanimeh O, Foxworth J, Gaur R. Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?. Annals of hematology 2019. link 85 Picardi M, Della Pepa R, Cerchione C, Pugliese N, Mortaruolo C, Trastulli F et al.. A Frontline Approach With Peripherally Inserted Versus Centrally Inserted Central Venous Catheters for Remission Induction Chemotherapy Phase of Acute Myeloid Leukemia: A Randomized Comparison. Clinical lymphoma, myeloma & leukemia 2019. link 86 Vu LP, Kharas MG. Targeting the Residual Leukemia Cells after Chemotherapy. Cancer cell 2018. link 87 Takahashi K. AML: Predicting the Unpredictable. Cell stem cell 2018. link 88 . Roots of AML Detectable Long before Symptoms. Cancer discovery 2018. link 89 . Data Offer New Insights into AML. Cancer discovery 2018. link 90 Zhang W, Sun S, Zhang W, Shi Z. Polymorphisms of ABCG2 and its impact on clinical relevance. Biochemical and biophysical research communications 2018. link 91 Diness BR, Risom L, Frandsen TL, Hansen B, Andersen MK, Schmiegelow K et al.. Putative new childhood leukemia cancer predisposition syndrome caused by germline bi-allelic missense mutations in DDX41. Genes, chromosomes & cancer 2018. link 92 Onec B, Okutan H, Albayrak M, Can ES, Aslan V, Koluman BU et al.. Combination therapy with azacitidine, etoposide, and cytarabine in the treatment of elderly acute myeloid leukemia patients: A single center experience. Journal of cancer research and therapeutics 2018. link 93 Shao X, Chen D, Xu P, Peng M, Guan C, Xie P et al.. Primary Philadelphia chromosome positive acute myeloid leukemia: A case report. Medicine 2018. link 94 Lowe JR, Yu Y, Wolf S, Samsa G, LeBlanc TW. A Cohort Study of Patient-Reported Outcomes and Healthcare Utilization in Acute Myeloid Leukemia Patients Receiving Active Cancer Therapy in the Last Six Months of Life. Journal of palliative medicine 2018. link 95 Yang X, Liu W, Lyons A, Song Z, Zhai S, Hu K. Pericarditis associated with cytarabine therapy for acute myelocytic leukemia: a case report. European journal of clinical pharmacology 2018. link 96 . Precision Medicine Promising for AML. Cancer discovery 2017. link 97 Jonas BA. On the origin of relapse in AML. Science translational medicine 2017. link 98 Cimmino L, Dolgalev I, Wang Y, Yoshimi A, Martin GH, Wang J et al.. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. Cell 2017. link 99 Van de Louw A. Effect of leukapheresis on blood coagulation in patients with hyperleukocytic acute myeloid leukemia. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2017. link 100 . Disruption of Core Circadian Clock Genes Reduces Leukemia Growth. Cancer discovery 2016. link

Original source

[1]
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party. — Cloos J, Valk PJM, Thiede C, Döhner K, Roboz GJ, Wood BL et al. Blood (2026)
[2]
American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. — Sekeres MA, Mattison R, Artz A, Baer MR, Chua CC, Demichelis-Gómez R et al. Blood advances (2026)
[3]
Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis. — Geels J, van Rhenen A, Gradowska P, Asselbergs FW, Linschoten M Leukemia (2026)
[4]
Posttransplant cyclophosphamide versus antithymocyte globulin in patients with cardiovascular comorbidity undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukaemia in first complete remission from unrelated donors: a retrospective matched-pair analysis from the ALWP of the EBMT. — Vydra J, Ferhat AT, Kröger N, Gedde-Dahl T, Eder M, Schroeder T et al. Bone marrow transplantation (2026)
[5]
Significance of the tendency for relative bradycardia during induction therapy for acute myeloid leukemia. — Tominaga R, Fujiwara SI, Honda S, Yokoyama D, Noguchi A, Furuki S et al. International journal of hematology (2026)
[6]
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy. — Dendorfer SM, Schmidt-Brücken K, Kramer M, Steffen B, Schliemann C, Mikesch JH et al. American journal of hematology (2026)
[7]
Prognostic impact of extramedullary disease in acute myeloid leukemia: A meta-analysis. — Lin Y, Liu P, Zhuang Q, Deng H, Liu X, Wang Y et al. International journal of cancer (2025)
[8]
Indirect treatment comparison of ivosidenib and other therapies in patients with newly diagnosed acute myeloid leukemia. — Gil-Sierra MD, Mantopoulos T, Barouma I, Hauch O, Teng Z, Fernandez C et al. Future oncology (London, England) (2025)
[9]
Myeloid sarcoma of the heart-A clinicopathological correlation. — Skok K, Zacharias M, Verheyen N, Hatzl S, Scholz L, Langner C et al. Wiener klinische Wochenschrift (2025)
[10]
Myeloid sarcoma with RBM15::MRTFA (MKL1) mimicking vascular neoplasm. — Gündoğdu F, Agaimy A, Aytaç S, Hazar V, Üner A, Kösemehmetoğlu K Virchows Archiv : an international journal of pathology (2025)
[11]
Predictors of Cardiac Recovery in Adults With AML Who Develop Heart Failure During Treatment. — Wu M, Russell K, Shaw CM, Halpern AB, Ghiuzeli C, Appelbaum JS et al. JCO oncology practice (2025)
[12]
Cardiotoxicity in patients with acute myeloid leukaemia following anthracycline-containing chemotherapy: A population-based matched cohort study. — Jensen RH, Teglgaard C, Jensen JF, Baech J, Marcher CW, Roug AS et al. British journal of haematology (2025)
[13]
Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis. — He H, Wen X, Zheng H Hematology (Amsterdam, Netherlands) (2024)
[14]
A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia. — Mohebbi A, Shahriyary F, Farrokhi V, Bandar B, Saki N Leukemia research (2024)
[15]
Characterization of relapse-supportive monocytic cells in acute myeloid leukemia. — Ng SWK Cell reports. Medicine (2024)
[16]
Synthetic Data Generation in Hematology - Paving the Way for OMOP and FHIR Integration. — Hahn W, Ahmadi N, Hoffmann K, Eckardt JN, Sedlmayr M, Wolfien M Studies in health technology and informatics (2024)
[17]
Covering Hierarchical Dirichlet Mixture Models on binary data to enhance genomic stratifications in onco-hematology. — Dall'Olio D, Sträng E, Turki AT, Tettero JM, Barbus M, Schulze-Rath R et al. PLoS computational biology (2024)
[18]
Variability in the perception of palliative care and end-of-life care among hematology professionals from the same reference center in Bahia, Brazil: A descriptive cross-sectional study. — Paim Miranda DL, Orathes Ponte Silva AM, Pereira Ferreira D, Teixeira da Silva L, Lins-Kusterer L, Queiroz Crusoé E et al. Sao Paulo medical journal = Revista paulista de medicina (2024)
[19]
Treating acute myelogenous leukemia in patients aged 70 and above: Recommendations from the International Society of Geriatric Oncology (SIOG). — Extermann M, Artz A, Rebollo MA, Klepin HD, Krug U, Loh KP et al. Journal of geriatric oncology (2024)
[20]
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. — Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM et al. Journal of the National Comprehensive Cancer Network : JNCCN (2023)
[21]
Cytogenetics in the management of acute myeloid leukemia and histiocytic/dendritic cell neoplasms: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH). — Bidet A, Quessada J, Cuccuini W, Decamp M, Lafage-Pochitaloff M, Luquet I et al. Current research in translational medicine (2023)
[22]
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis. — Daver NG, Iqbal S, Renard C, Chan RJ, Hasegawa K, Hu H et al. Journal of hematology & oncology (2023)
[23]
Improved detection of measurable residual disease in acute myeloid leukemia. — Zhang X, Grimes HL Science advances (2023)
[24]
A Trifunctional Natural Killer Cell Engager Can Target CD123+ Leukemia. Cancer discovery (2023)
[25]
A 42-Year-Old Man with a Seizure. — Mansour MA, Burns TC, El-Sokkary S, Ayad AA NEJM evidence (2023)
[26]
Factors influencing access to specialised haematology units during acute myeloblastic leukaemia patient care: A population-based study in France. — Atsou KM, Rachet B, Cornet E, Chretien ML, Rossi C, Remontet L et al. Cancer medicine (2023)
[27]
MarrowQuant 2.0: A Digital Pathology Workflow Assisting Bone Marrow Evaluation in Experimental and Clinical Hematology. — Sarkis R, Burri O, Royer-Chardon C, Schyrr F, Blum S, Costanza M et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (2023)
[28]
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). — Marchesi F, Salmanton-García J, Emarah Z, Piukovics K, Nucci M, López-García A et al. Haematologica (2023)
[29]
Multiple Organ Dysfunction and Critically Ill Children With Acute Myeloid Leukemia: Single-Center Retrospective Cohort Study. — Gaugler M, Swinger N, Rahrig AL, Skiles J, Rowan CM Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies (2023)
[30]
Acute Myeloid Leukemia: Challenges in Delivering End-of-Life Care. — Koets V, Montagnini M The American journal of hospice & palliative care (2023)
[31]
The role of cadmium in the pathogenesis of myeloid leukemia in individuals with anemia, deficiencies in vitamin D, zinc, and low calcium dietary intake. — Djulejic V, Petrovic B, Jevtic J, Vujacic M, Clarke BL, Cirovic A et al. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) (2023)
[32]
Vitamin D-Binding Protein and Acute Myeloid Leukemia: A Genetic Association Analysis in Combination with Vitamin D Levels. — Ghazaey Zidanloo S, Jahantigh D, Amini N Nutrition and cancer (2023)
[33]
External validation of a heart failure risk score in patients with acute myeloid leukemia. — Doukas PG, Cascino GJ, Meng Z, Baldridge AS, Kang Y, Scherrer-Crosbie M et al. Leukemia & lymphoma (2023)
[34]
The Use of Extracorporeal Membrane Oxygenation as a Bridge to Bone Marrow Transplantation in a Patient With High-risk Acute Myeloid Leukemia. — Nader M, Bonde P, Massaro S, Giuliano JS, Shah N Journal of pediatric hematology/oncology (2023)
[35]
Venous thromboembolism and acute myeloid leukemia: risk factors and mortality in elderly white, black and Asian patients. — Faiz AS, Guo S, Sridharan A, Lin Y, Philipp CS Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis (2023)
[36]
Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis. — Li L, Han C, Yu X, Shen J, Cao Y Journal of healthcare engineering (2022)
[37]
Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. — Stemler J, de Jonge N, Skoetz N, Sinkó J, Brüggemann RJ, Busca A et al. The Lancet. Haematology (2022)
[38]
Azacitidine maintenance in AML post induction and posttransplant. — Bewersdorf JP, Prebet T, Gowda L Current opinion in hematology (2022)
[39]
Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis. — Lipilkin PV, Kulaeva ED, Mashkina EV Leukemia research (2022)
[40]
Evidence-based support for phenotypic drug discovery in acute myeloid leukemia. — Vandersluis S, Reid JC, Orlando L, Bhatia M Drug discovery today (2022)
[41]
Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia. — Solana-Altabella A, Ballesta-López O, Megías-Vericat JE, Martínez-Cuadrón D, Montesinos P Expert opinion on emerging drugs (2022)
[42]
Telehealth Use in Rural North Carolina Counties: Perceptions Among Patients With Acute Myeloid Leukemia. — Woodard A, Eche IJ, Leak Bryant A Clinical journal of oncology nursing (2022)
[43]
Ceramide Accumulation Induces the Integrated Stress Response in AML. Cancer discovery (2022)
[44]
The challenge of targets and drug discovery using large-scale screening approaches in onco-hematology. — Benajiba L, Kiladjian JJ Therapie (2022)
[45]
Safety Concerns Prompt Pause of Magrolimab Trials. Cancer discovery (2022)
[46]
Aberrant Phenotype in Acute Myeloid Leukemia: Hematology Laboratory Experiment of the University Hospital of Casablanca, Morocco. — Jaddaoui S, Bencharef H, Addakiri S, Oukkache B Clinical laboratory (2022)
[47]
Nutrition-related problems, nutritional support practices and barriers to adherence to nutritional guidelines during intensive treatment for acute myeloid leukemia: Patients' and hematology nurses' perspectives and experiences. — van Lieshout R, Lize N, Tick LW, van Deursen J, Driessen E, Janssen T et al. Clinical nutrition ESPEN (2022)
[48]
A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel. — Šestáková Š, Cerovská E, Šálek C, Kundrát D, Ježíšková I, Folta A et al. Clinical epigenetics (2022)
[49]
Bereaved Informal Caregivers Rarely Recall a Relationship Between Transfusions and Hospice in Acute Myeloid Leukemia. — Cripe LD, Cottingham AH, Martin CE, Hoffmann ML, Sargent K, Baker LB The American journal of hospice & palliative care (2022)
[50]
Pediatric AML patients with acute-onset cardiomyopathy in the setting of Streptococcus viridans bacteremia after anthracyclines. — Sabet K, Panigrahi A, Chung J, Dayan Y Pediatric blood & cancer (2022)
[51]
Intracranial hemorrhage in newly diagnosed non-promyelocytic acute myeloid leukemia patients admitted for intensive induction chemotherapy. — Koschade SE, Stratmann JA, Miesbach W, Steffen B, Serve H, Finkelmeier F et al. European journal of haematology (2022)
[52]
Abdominal Complications During Treatment for Pediatric Acute Myeloid Leukemia. — Borgstedt-Bendixen SE, Abrahamsson J, Ha SY, Koskenvuo M, Lausen B, Palle J et al. Journal of pediatric hematology/oncology (2022)
[53]
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. — Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR et al. Journal of the National Comprehensive Cancer Network : JNCCN (2021)
[54]
Treatment Outcomes of Intracranial Myeloid Sarcomas: A Meta-Analysis. — Lee D, Omofoye OA, Nuño MA, Riestenberg RA, Shahlaie K World neurosurgery (2021)
[55]
Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review. — Chang Y, Guyatt GH, Teich T, Dawdy JL, Shahid S, Altman JK et al. PloS one (2021)
[56]
Meta-analysis of gene signatures and key pathways indicates suppression of JNK pathway as a regulator of chemo-resistance in AML. — Modarres P, Mohamadi Farsani F, Nekouie AA, Vallian S Scientific reports (2021)
[57]
Benefits of AML Maintenance Therapy Extend to Quality of Life and Hospitalization. The oncologist (2021)
[58]
Mutations Synergize to Alter Epigenetic and Genomic Landscape of AML. Cancer discovery (2021)
[59]
Single-Cell Sequencing Reveals Clonal Architecture of Myeloid Cancers. Cancer discovery (2021)
[60]
African American Race Predicts Poor Survival in Younger Adults with AML. The oncologist (2021)
[61]
Maintenance Therapy Improves AML Outcomes Regardless of MRD Status or Consolidation Cycles. The oncologist (2021)
[62]
The Age-Old Conundrum With Thiopurines: Are the Accumulating Risks Greater Than Benefits? — Ha C The American journal of gastroenterology (2021)
[63]
A Splenic Infarction Related to Parainfluenza Infection in a Patient with AML: Lessons for COVID-19. — Sahu KK, E Vogt B, Shanahan L, Cerny J Acta bio-medica : Atenei Parmensis (2021)
[64]
Study Offers Insights on Prognostic Significance of IDH Mutations Across Age Groups in AML. The oncologist (2021)
[65]
Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative. — Corboy G, Othman J, Lee L, Wei A, Ivey A, Blombery P et al. Pathology (2021)
[66]
Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes. — Yu S, Fan Z, Ma L, Wang Y, Huang F, Zhang Q et al. JAMA network open (2021)
[67]
Impact of enhanced haematology palliative care services in patients with myelodysplastic syndrome and acute myeloid leukaemia: study protocol for a randomized controlled trial. — Chan KY, Gill H, Li CW, Chan TSY, Au HY, Wong CY et al. Annals of palliative medicine (2021)
[68]
IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis. — Kattih B, Shirvani A, Klement P, Garrido AM, Gabdoulline R, Liebich A et al. Leukemia (2021)
[69]
Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience. — Hosono N, Ookura M, Araie H, Morita M, Itoh K, Matsuda Y et al. International journal of hematology (2021)
[70]
Low doses of gemtuzumab ozogamicin in adults diagnosed with acute myeloid leukaemia. — Peña Domingo M, Vives Polo S, Garrido Díaz A, Coll Jordà R, Ribera Santasusana JM, Ferrá Coll C Medicina clinica (2021)
[71]
Anthracycline-related acute cardiotoxicity in a very young Omani patient with acute myeloid leukaemia. — Tony S, Mevada R, Joshi N Cardiology in the young (2021)
[72]
Congenital acute myeloid leukemia: challenges and lessons. A 15-year experience from the UK. — Green K, Tandon S, Ahmed M, Toscano W, O'Connor D, Ancliff P et al. Leukemia & lymphoma (2021)
[73]
Preleukemic Cells Can Be Eliminated in Cancer discovery (2020)
[74]
Informed consent for genetic testing in hematology. — Marron JM Hematology. American Society of Hematology. Education Program (2020)
[75]
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. — Sekeres MA, Guyatt G, Abel G, Alibhai S, Altman JK, Buckstein R et al. Blood advances (2020)
[76]
Screening for Dental Infections Achieves 6-Fold Reduction in Dental Emergencies During Induction Chemotherapy for Acute Myeloid Leukemia. — Watson EE, Metcalfe JE, Kreher MR, Maxymiw WG, Glogauer M, Schimmer AD JCO oncology practice (2020)
[77]
Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia. — Dhakal P, Lyden E, Muir KE, Al-Kadhimi ZS, Koll T, Maness LJ et al. Leukemia & lymphoma (2020)
[78]
Evaluation of cardiomyopathy in acute myeloid leukemia patients treated with anthracyclines. — Mort MK, Sen JM, Morris AL, DeGregory KA, McLoughlin EM, Mort JF et al. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
[79]
Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. — Ho VT, Martin AS, Pérez WS, Steinert P, Zhang MJ, Chirnomas D et al. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (2020)
[80]
Ivosidenib induction therapy complicated by myopericarditis and cardiogenic shock: A case report and literature review. — Hernandez Burgos P, Patel J, Chen A Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
[81]
Alternative Effective and Safe Induction Regimens for Newly Diagnosed Acute Myeloid Leukemia in Patients With Cardiac Contraindication to Anthracyclines. — Marcault C, Venton G, Gastaud L, Mannone L, Rey J, D'Incan E et al. Clinical lymphoma, myeloma & leukemia (2020)
[82]
Cutting Off Leukemogenesis: Hydra-like Plasticity of Mature Leukemic Cells. — Bamezai S, Buske C Cell stem cell (2019)
[83]
Acute Myeloid Leukemia: Update on Upfront Therapy in Elderly Patients. — Keiffer G, Palmisiano N Current oncology reports (2019)
[84]
Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand? — Qasrawi A, Bahaj W, Qasrawi L, Abughanimeh O, Foxworth J, Gaur R Annals of hematology (2019)
[85]
A Frontline Approach With Peripherally Inserted Versus Centrally Inserted Central Venous Catheters for Remission Induction Chemotherapy Phase of Acute Myeloid Leukemia: A Randomized Comparison. — Picardi M, Della Pepa R, Cerchione C, Pugliese N, Mortaruolo C, Trastulli F et al. Clinical lymphoma, myeloma & leukemia (2019)
[86]
Targeting the Residual Leukemia Cells after Chemotherapy. — Vu LP, Kharas MG Cancer cell (2018)
[87]
AML: Predicting the Unpredictable. — Takahashi K Cell stem cell (2018)
[88]
Roots of AML Detectable Long before Symptoms. Cancer discovery (2018)
[89]
Data Offer New Insights into AML. Cancer discovery (2018)
[90]
Polymorphisms of ABCG2 and its impact on clinical relevance. — Zhang W, Sun S, Zhang W, Shi Z Biochemical and biophysical research communications (2018)
[91]
Putative new childhood leukemia cancer predisposition syndrome caused by germline bi-allelic missense mutations in DDX41. — Diness BR, Risom L, Frandsen TL, Hansen B, Andersen MK, Schmiegelow K et al. Genes, chromosomes & cancer (2018)
[92]
Combination therapy with azacitidine, etoposide, and cytarabine in the treatment of elderly acute myeloid leukemia patients: A single center experience. — Onec B, Okutan H, Albayrak M, Can ES, Aslan V, Koluman BU et al. Journal of cancer research and therapeutics (2018)
[93]
Primary Philadelphia chromosome positive acute myeloid leukemia: A case report. — Shao X, Chen D, Xu P, Peng M, Guan C, Xie P et al. Medicine (2018)
[94]
A Cohort Study of Patient-Reported Outcomes and Healthcare Utilization in Acute Myeloid Leukemia Patients Receiving Active Cancer Therapy in the Last Six Months of Life. — Lowe JR, Yu Y, Wolf S, Samsa G, LeBlanc TW Journal of palliative medicine (2018)
[95]
Pericarditis associated with cytarabine therapy for acute myelocytic leukemia: a case report. — Yang X, Liu W, Lyons A, Song Z, Zhai S, Hu K European journal of clinical pharmacology (2018)
[96]
Precision Medicine Promising for AML. Cancer discovery (2017)
[97]
On the origin of relapse in AML. — Jonas BA Science translational medicine (2017)
[98]
Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. — Cimmino L, Dolgalev I, Wang Y, Yoshimi A, Martin GH, Wang J et al. Cell (2017)
[99]
Effect of leukapheresis on blood coagulation in patients with hyperleukocytic acute myeloid leukemia. — Van de Louw A Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis (2017)
[100]
Disruption of Core Circadian Clock Genes Reduces Leukemia Growth. Cancer discovery (2016)

Share:Twitter Reddit LinkedIn